Abstract
Heparin is a highly sulfated glycosaminoglycan found in secretory granules of mast cells. It is known for its anticoagulant activity and used for various coagulation disorders and vascular problems. Recently, more novel actions other than the anticoagulant function have been identified. It was reported to promote gastric ulcer healing and inhibit inflammation in the colon. These actions were shown to be mediated through the increase of expressions and functions of various growth factors, such as basic fibroblast growth factor, epidermal growth factor and insulin-like growth factor. Heparin also stimulated the gastric mucus synthesis via activation of nitric oxide synthase. This article summarizes these actions and reports the potential therapeutic application of heparin on gastric ulcer and ulcerative colitis both in animals and humans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Arai, T., et al. (1996a). Binding of insulin-like growth factors I and II to IGF-binding protein-2 enables it to bind heparin and extracellular matrix, Endocrinology 137, 4571–4575.
Arai, T., et al. (1996b). Substitution of specific amino-acids in insulin-like growth factor binding protein-5 alters heparin binding and its change in affinity for IGF-1 response to heparin, J. Biol. Chem. 271, 6099–6106.
Aviezer, D., et al. (1994). Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor, J. Biol. Chem. 269, 114–121.
Beck, P. L. and Podolsky, D. K. (1999). Growth factors in in' ammatory bowel diseases, Infl amm. Bowel Dis. 5, 44–60.
Bernfield, M., et al. (1992). Biology of the syndecans: a family of transmembrane proteoglycans, Annu. Rev. Vell. Biol. 8, 365–393.
Brazier, F., et al. (1996). Treatment of ulcerative colitis with heparin, Gastroenterology 110, A872 (Abstract).
Brickman, Y. G., et al. (1995). Heparan sulfates mediate the binding of basic fibroblast growth factor to a specific receptor on neural precursor cells, J. Biol. Chem. 270, 24941–24948.
Chong, B. H. (1996). Anticoagulation, Aust. Fam. Physician 25, 74–78.
Christensen, H., et al. (1993). Effects of growth hormone on the in' ammatory activity of experimental colitis in rats, Scand. J. Gastroenterol. 28, 503–511.
Day, R., et al. (1991). Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy, Dig. Dis. Sci. 44, 2508–2515.
Diamond, M. S., et al. (1995). Heparin is an adhesive ligand for the leucocyte integrin Mac-1 (CD11b/ CD18), J. Cell Biol. 130, 1473–1482.
Evans, R. C., et al. (1997). Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases, Aliment. Pharmacol. Ther. 11, 1037–1040.
Folwaczny, C., et al. (1999). Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease, Am. J. Gastroenterol. 94, 1551–1555.
Fong, S., et al. (1997). Mucosal addressin cell adhesion molecule 1. Its binding motif for alpha-4 beta-7 and role in experimental colitis, Immunol. Res. 16, 299–311.
Gaffney, P. R. and Gaffney, A. (1996). Heparin therapy in refractory ulcerative colitis — an update, Gastroenterology 110, A913 (Abstract).
Gaffney, P. R., et al. (1995). Paradoxical response to heparin in 10 patients with ulcerative colitis, Am. J. Gastroenterol. 90, 220–223.
Galiano, R. D., et al. (1996). Interactions between the insulin-like growth factor family and integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model, J. Clin. Immunol. 98, 2462–2468.
Garner, M. H., et al. (1992). Insulin-like growth factor I and II expression in the healing wound, J. Surg. Res. 52, 389–394.
Gibson, P. R. (1997). Ulcerative colitis: an epithelial disease?, Ballieres Clin. Gastroenterol. 11, 17–33.
Hirsh, J., et al. (1995). Heparin: mechanism of action, Pharmacokinetics, dosing consideration, monitoring, efficacy, and safety, Chest 108, 258S–275S.
Hunt, T. K. (1990). Basic principles of wound healing, J. Trauma 12 (Suppl.) S122–S128.
Inauen, W., et al. (1988). Influence of prostaglandins, omeprazole, and indomethacin on healing of experimental gastric ulcers in the rat, Gastroenterology 95, 636–641.
Kan, M., et al. (1996). Divalent cations and heparin/ heparan sulphate co-operate to control assembly and activity of the FGF receptor complex, J. Biol. Chem. 271, 26143–26148.
Koedam, J. A., et al. (1997). Insulin-like growth factor binding proteins-3 and-5 formdodecyl sulfate-stable multimers, Biochem. Biophys. Res. Commun. 240, 707–714.
Koenig, A., et al. (1998). Differential interactionsbetween heparin and heparan sulphate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents, J. Clin. Immunol. 101, 877–889.
Li, Y., et al. (1998). Healing effects of heparin on acetic acid-inducedgastric ulcers in rats, Chin. Med. J. (Engl.) 111, 12–16.
Li, Y., et al. (1999). Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats, J. Pharmacol. Exp. Ther. 290, 789–796.
Li, Y., et al. (2000). Intragastric administration of heparin enhances gastric ulcer healing through a nitric oxide-dependent mechanism in rats, Eur. J. Pharmacol. 399, 205–214.
Li, Y., et al. (2001). A 3.0-kDa low molecular weight heparin promotes gastric ulcer healing in rats, Aliment. Pharmacol. Ther. 15, 2009–2017.
Lichtiger, S., et al. (1994). Cyclosporin in severe ulcerative colitis refractory to steroid therapy, New Engl. J. Med. 330, 1841–1845.
Majerus, P. W., Broze, G. J. Jr, Miletich, J. P., et al. (1996). Anticoagulant, thrombolytic, and antiplatelet drugs, in: Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th edn, Hardman, J. G., Gilman and Limbard, L. E. (Eds), pp. 1341–1359. McGraw Hill, New York.
Michell, N. P., et al. (1997). Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein-2 in colonic cancers, Br. J. Cancer 76, 60–66.
Rechler, M. M. and Brown, D. (1994). Insulin-like growth factor binding proteins, Vitam. Horm. 47, 1–114.
Robbins, S. L. (1989). Healing and repair, in: Robbins Pathologic Basis of Disease, Cotran, R. S. and Kumar, V. (Eds), pp. 71–86. WB Saunders, Philadelphia, PA.
Russo, V. C., et al. (1997). IGFBP-2 binds to cell surface proteoglycan in rat olfactory bulb, Endocrinology 138, 4858–4867.
Schwall, R. H., et al. (1996). Heparin induces dimerisation and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2, J. Cell Biol. 133, 709–718.
Spivak-Kroizman, T., et al. (1994). Heparin-induced oligomerisationof FGF molecules is responsible for FGF receptor dimerisation, activation, and cell proliferation, Cell 79, 1014–1015.
Steenfos, H. H. and Jansson, J. Q. (1992). Gene expression of insulin-like growth factor I and IGF-1 receptor during wound healing in rats, Eur. J. Surg. 158, 327–331.
Steinfeld, R., et al. (1996). Stimulation of febroblast growth factor receptor-1 occupancy and signaling by cell surface-associatedsyndecans and glypican, J. Cell. Biol. 133, 405–416.
Suh, D. Y., et al. (1992). Insulin-like growth factor I reverses the impairment of wound healing induced by corticosteroids in rats, Endocrinology 131, 2399–2404.
Tarnawski, A. and Erickson, R. A. (1991). Sucralfate-24 years later: current concepts of its protective and therapeutic actions, Eur. J. Gastroenterol. Hepatol. 3, 795–810.
Tarnawski, A., et al. (1990). Vascular and microvascular changes — key factors in the development of acetic acid-induced gastric ulcers in rats, J. Clin. Gastroenterol. 12 (Suppl. 1), S148–S157.
Thompson, N. P., et al. (1995). Inherited disorders of coagulation appear to protect against infl ammatory bowel disease, Gastroenterology 108, 1011–1015.
Torkvist, L., et al. (1999). Low molecular weight heparin as adjunct therapy in active ulcerative colitis, Aliment. Pharmacol. Ther. 13, 1323–1328.
Vlodavsky, I., et al. (1992). Expression of heparanases by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation, Invasion Metastasis 12, 493–499.
Yayon, A., et al. (1995). Ligand binding by fibroblast growth factor receptors investigated using chimeric receptor molecules, J. Receptor Signal Transduction 15, 185–197.
Zeeh, J. M., et al. (1995). Up-regulation of insulinlike growth factor I binding sites in experimental colitis in rats, Gastroenterology 108, 644–652.
Zeeh, J. M., et al. (1996). Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats, Gastroenterology 110, 1077–1083.
Rights and permissions
About this article
Cite this article
Ye, Y.N., Li, Y., Koo, M.W.L. et al. A new role of heparin: A polysaccharide for gastrointestinal diseases. Inflammopharmacology 10, 365–374 (2002). https://doi.org/10.1163/156856002321544837
Issue Date:
DOI: https://doi.org/10.1163/156856002321544837